Search results
Eli Lilly's Weight-Loss Drug Still Going Strong, Boosts Annual Forecast
Benzinga via AOL· 3 days agoThe volume increase was primarily driven by growth from Mounjaro, Zepbound, Verzenio, and Jardiance,...
Earnings Season: 3 Companies Boosting Guidance
Zacks via Yahoo Finance· 13 hours agoEarnings season continues to chug along, with results from many companies already delivered. And concerning positivity, all three of these companies'...
Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
Zacks via Yahoo Finance· 3 days agoEli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises...
Decoding Eli Lilly and Co (LLY): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 2 days agoThe financial overview indicates that LLY has experienced revenue growth driven by increased volume...
Eli Lilly and Company (NYSE:LLY) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 17 hours agoEli Lilly and Company (NYSE:LLY) Q1 2024 Earnings Call Transcript April 30, 2024 Eli Lilly and...
Unpacking the Latest Options Trading Trends in Eli Lilly and Co - Eli Lilly and Co (NYSE:LLY)
Benzinga· 17 hours agoLilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology. Current ...
Is Eli Lilly Stock A Buy After Weight-Loss Drug Crushes Quarterly Sales Forecasts?
Investor's Business Daily· 3 days agoTrulicity, another diabetes treatment, had $1.46 billion in first-quarter sales, down 26% and below...
Eli Lilly’s stock jumps as first-quarter profit tops estimates amid strong sales of Mounjaro,...
Market Watch· 3 days agoEli Lilly & Co. shares gained 7% premarket on Tuesday after the company reported first-quarter...
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
Zacks via Yahoo Finance· 2 days agoEli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity...
IBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views
Investor's Business Daily· 2 days agoHe kept his in-line (neutral) rating on Eli Lilly stock. Sales of other key products, cancer drug...
